Category Archives: PCa Treatments

Provenge available for men with advanced prostate cancer at Roswell Park

February 7 2011, BUFFALO, NY — The nation’s first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements. Continue reading Provenge available for men with advanced prostate cancer at Roswell Park

How does a robotic prostatectomy work?

Robot assisted prostate surgery, known medically as the da Vinci prostatectomy, has had a profound influence over treatment during the past decade. Robotic surgical technology was first developed by the military for use in the battlefield. However during the past decade, this technology has been rapidly applied to the general medical setting, notably in the field of prostate cancer. Continue reading How does a robotic prostatectomy work?

Dendreon Sets Provenge Price at $93,000 – Only 2,000 Patients Will Get it in First Year

Dendreon is pricing Provenge high and for the first year its availability will be low, according to a report today in Xconomy, a Seattle business website. Provenge, the first immunotherapy to win FDA approval for treatment of men with prostate cancer, will cost $93,000 per patient. Only 2,000 patients will be treated with Provenge in the first year.
Continue reading Dendreon Sets Provenge Price at $93,000 – Only 2,000 Patients Will Get it in First Year

FDA Approves PROVENGE ® for the Treatment of Men with Advanced Prostate Cancer

SEATTLE, April 29, 2010 –Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(®) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). Provenge is designed to induce an immune response against Prostatic Acid Phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.
Continue reading FDA Approves PROVENGE ® for the Treatment of Men with Advanced Prostate Cancer

Phase 3 Trial Underway for MDV 3100 for Advanced Prostate Cancer

In light of favorable results from the Phase 1-2 trial of MDV 3100 for advanced prostate cancer, a Phase 3 trial is enrolling at sites in the US, Canada, South America, UK, Europe, Australia, and South Africa. Results from the earlier trial are published online by the UK medical journal The Lancet. Continue reading Phase 3 Trial Underway for MDV 3100 for Advanced Prostate Cancer